<DOC>
	<DOCNO>NCT01267396</DOCNO>
	<brief_summary>The objective study compare evaluate single-dose oral bioavailability test formulation Sertraline Hydrochloride 100 mg tablet ( Dr. Reddy 's Laboratories Limited ) reference formulation ZOLOFT® 100 mg Tablet ( Pfizer ) fast condition healthy adult human subject .</brief_summary>
	<brief_title>Bioequivalence Study Sertraline Hydrochloride Tablets 100 mg Under Fasting Conditions</brief_title>
	<detailed_description>Open Label , Balanced , Randomized , Two Treatment , Two Sequence , Two Period , Single-dose , Crossover , Oral Bioequivalence Study Sertraline Hydrochloride 100 mg Tablets ( Dr. Reddy 's Laboratories Limited , India ) With Reference Formulation ZOLOFT® 100 mg Tablet ( Pfizer , USA ) Under Fasting Conditions Healthy Human Adult Subjects . 32 healthy , adult , human male subject enrol study subject complete period .</detailed_description>
	<mesh_term>Sertraline</mesh_term>
	<criteria>1 . Healthy human subject age 18 45 year ( include ) . 2 . Subjects weight within normal range accord normal value body mass index ( 18.5 24.9 kg/m2 ) minimum 50 kg weight . 3 . Subjects normal health determine personal medical history , clinical examination laboratory examination within clinically acceptable normal rane . 4 . Subjects normal 12lead electrocardiogram ( ECG ) 5 . Subjects normal chest XRay ( P/A view ) 6 . Subjects negative urine screen drug abuse ( include amphetamine , barbiturate , benzodiazepine , marijuana , cocaine , morphine ) . 7 . Subjects negative alcohol breath test 8 . Subjects willing adhere protocol requirement provide write informed consent . For Female Subjects : 1 . Female child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine devise ( IUD ) abstinence , 2 . Postmenopausal least 1 year 3 . Surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject . 1 . Hypersensitivity sertraline hydrochloride related class drug . 2 . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunological , dermatological neurological psychiatric disease disorder . 3 . Any treatment could bring induction inhibition hepatic microsomal enzyme system within 1 month study start . 4 . History presence significant alcoholism drug abuse past one year . 5 . History presence significant smoking ( 10 cigarette day ) consumption tobacco product . 6 . History presence significant asthma , urticaria allergic reaction . 7 . History presence significant gastric and/or duodenal ulceration . 8 . History presence significant thyroid disease , adrenal dysfunction , organic intracranial lesion pituitary tumor . 9 . History presence cancer 10 . History presence significant easy bruise bleed 11 . History presence significant recent trauma 12 . Subjects abnormal diet ( whatever reason ) four week precede study . 13 . Difficulty donate blood 14 . Difficulty swallow solid like tablet capsule 15 . Systolic blood pressure le 100 mm Hg 140 mm Hg 16 . Diastolic blood pressure le 60 mm Hg 90 mm Hg . 17 . Pulse rate le 50/minute 100/minute 18 . Oral temperature le 95ºF 98.6ºF . 19 . Respiratory rate le 12/minute 20/minute 20 . Use prescribed medication last two week OTC medical product last week prior initiation study 21 . Major illness 3 month screen 22 . Participation drug research study within past 3 month 23 . Donation blood past 3 month screen . For Female Subjects : Female subject pregnant able ( woman child bear potential ) become pregnant study allow participate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Sertraline</keyword>
	<keyword>crossover</keyword>
</DOC>